Infliximab for ipilimumab-induced colitis: A series of 13 patients

Asia-Pacific Journal of Clinical Oncology

Volumn 13, Issue 5, 2017, Pages e284-e290

  Hillock, Nadine T ^a   Heard, Sharryn ^b   Kichenadasse, Ganessan ^c   Hill, Catherine L ^d   Andrews, Jane ^b  

^a South Australian Medicines Evaluation Panel   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c FLINDERS MEDICAL CENTRE   (Australia)

^d QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

colitis; Immune mediated colitis; infliximab; ipilimumab; melanoma

Indexed keywords

CORTICOSTEROID; INFLIXIMAB; IPILIMUMAB; GASTROINTESTINAL AGENT;

ADULT; AGED; ARTICLE; AUSTRALIA; CLINICAL ARTICLE; CLINICAL OUTCOME; COLITIS; DIARRHEA; DISEASE SEVERITY; DRUG INDUCED DISEASE; DRUG MEGADOSE; FEMALE; HOSPITALIZATION; HUMAN; MALE; METASTATIC MELANOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUBLIC HOSPITAL; REPEATED DRUG DOSE; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; CHEMICALLY INDUCED; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COLITIS; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INFLIXIMAB; IPILIMUMAB; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 85006921234     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/ajco.12651     Document Type: Article

References (21)

1. Bristol-Myers Squibb Australia Pty Ltd. Yervoy (Ipilimumab) Product Information. 2013.
2. Hodi F, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363(8): 711–23.
3. Bristol-Myers Squibb. Personal communication. 2014.
4. Pharmaceutical Benefits Advisory Committee. Public summary document - ipilimumab (Yervoy). For unresectable stage III or stage IV malignant melanoma. Canberra. [Cited 28 January 2015] Available from URL: http://www.pbs.gov.au/industry/listing/elements/tpbac-meetings/psd/2012-11/ipilimumab.pdf. 2012.
5. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353(23): 2462–76.
6. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359(9317): 1541–9.
7. Janssen Cilag Pty Ltd. Remicade (infliximab) Product Information. 2014.
8. Travis SP, Farrant JM, Ricketts C et al. Predicting outcome in severe ulcerative colitis. Gut 1996; 38(6): 905–10.
9. EviQ Cancer Treatments Online (webpage). Malignant melanoma metastatic ipilimumab. NSW Government & Cancer Institute of NSW. [Cited 8 Jan 2015] Available from URL: https://www.eviq.org.au/Protocol/tabid/au/Protocol/tabid/66/id/1307/view/IRAE/Malignant66/id/1307/view/IRAE/Malignant+Melanoma+Metastatic+Ipilimumab.aspx?popup=1.
10. Bristol-Myers Squibb Australia Pty Ltd. Yervoy (ipilimumab) immune-related adverse reaction (irAR) management guide. Mulgrave, VIC. 2013.
11. Merrill S, Reynolds P, Kalra A et al. Early administration of infliximab for severe ipilimumab-related diarrhea in a critically ill patient. Ann Pharmacother 2014; 48(6): 806–10.
12. Khirfan K, Kistin M. Colitis associated with biological agents. Dig Dis Sci 2014; 59(6): 1112–4.
13. Pages C, Gornet JM, Monsel G et al. Ipilimumab-induced acute severe colitis treated by infliximab. Melanoma Res 2013; 23(3): 227–30.
14. Freeman H. Colitis associated with biological agents. World J Gastroenterol 2012; 18(16): 1871–4.
15. Lord J, Hackman RC, Moklebust A et al. Refractory colitis followinganti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cells. Dig Dis Sci 2010; 55(5): 1396–405.
16. Johnston R, Lutzky J, Chodhry A, Barkin JS. Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab. Dig Dis Sci 2009; 54(11): 2538–40.
17. Minor D, Chin K, Kashani-Sabet M. Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis. Cancer Biother Radiopharm 2009; 24(3): 321–5.
18. Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 2007; 12(7): 864–72.
19. Lee LYW, Sanderson JD, Irving PM. Anti-infliximab antibodies in inflammatory bowel disease: prevalence, infusion reactions, immunosuppression and response, a meta-analysis. Eur J Gastroenterol Hepatol 2012; 24(9): 1078–85.
20. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010; 105(3): 501–23.
21. Lam T, Chan MMK, Sweeting AN et al. Ipilimumab-induced hypophysitis in melanoma patients: an Australian case series. Intern Med J 2015: 45(10): 1066–73.